Saturday 17 October 2026
Export CTKB’s income statement to Excel — free account
Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024. In the quarter to June 2026, revenue grew 5.57%, EPS fell 125.0%, free cash flow grew 42.5% and total debt fell 68.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
5.24
0.17
−3.14%
Follow CTKB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 6 | 4 | 2 | 5 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 541.18 | 5,100.00 | 36.38 | 36.38 | — |
Altman Z-Score |
3.89 | 5.86 | 8.24 | 9.97 | 14.29 | — | — | — |
P/S ratio |
3.20 | 4.23 | 6.22 | 8.30 | 9.79 | 6.05 | 6.05 | — |
P/FCF ratio |
0.00 | 38.64 | 3,208.45 | 0.00 | 4,708.38 | 63.51 | 63.51 | — |
Altman Z″-Score (non-manufacturers) |
6.15 | 7.82 | 7.96 | 9.74 | 12.99 | 10.00 | 3.82 | — |
Beneish M-Score |
(3.30) | (2.75) | (2.29) | (1.71) | (1.73) | (1.92) | — | — |
P/Operating CF |
(836.73) | 424.47 | 126.15 | 219.80 | 229.89 | (152.80) | (152.80) | — |
P/B ratio |
1.89 | 2.14 | 3.05 | 3.20 | 3.09 | 0.00 | 0.00 | — |
Price to Tangible BV |
2.09 | 2.36 | 3.39 | 3.31 | 3.21 | 0.00 | 0.00 | — |
EV/Sales |
1.91 | 2.85 | 4.86 | 6.21 | 6.94 | 4.43 | 4.43 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 264.46 | 85.37 | 36.57 | 36.57 | — |
EV/Operating CF |
(81.97) | 22.49 | 177.78 | (83.35) | 191.75 | 36.97 | 36.97 | — |
EV/FCF |
(44.54) | 26.02 | 2,510.34 | (46.38) | 3,337.63 | 46.54 | 46.54 | — |
Quick Ratio |
4.16 | 5.00 | 5.67 | 8.01 | 11.89 | 6.90 | 2.28 | — |
Current Ratio |
5.04 | 5.86 | 6.97 | 9.26 | 13.01 | 7.86 | 3.22 | — |
Net Debt/EBITDA |
9.19 | 27.59 | 14.03 | (88.66) | (35.06) | (11.65) | (9.84) | — |
Debt/Assets |
0.11% | 0.21% | 0.33% | 0.44% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.42 | 0.40 | 0.38 | 0.33 | 0.37 | 0.64 | 1.63 | — |
Operating CF/Net income |
0.07 | (4.22) | (0.43) | (4.75) | 0.00 | 4.71 | 0.82 | — |
Capex/Depreciation |
(0.33) | (0.33) | (0.52) | (1.74) | (3.51) | (2.57) | 0.00 | — |
Interest Coverage |
(85.20) | 3.92 | (13.45) | (0.70) | 5.26 | 41.02 | 7.76 | — |
| (18.05%) | (1.53%) | (2.97%) | 0.62% | 0.00% | (11.14%) | 58.30% | — | |
| (13.85%) | (1.21%) | (2.40%) | 0.52% | 0.00% | 2.21% | (47.41%) | — | |
ROIC |
(31.26%) | (10.79%) | (13.19%) | (1.35%) | 14.04% | 70.14% | 0.00% | — |
Return on Tangible Assets |
(20.03%) | (1.74%) | (3.43%) | 0.62% | 0.00% | 1.75% | (35.23%) | — |
Average Days of Receivables |
113.23 | 110.32 | 105.76 | 108.73 | 84.90 | 66.80 | 111.90 | — |
Research and Development Expense of Revenue |
18.10% | 19.66% | 22.87% | 21.25% | 19.10% | 14.75% | 15.43% | — |
Selling, General and Administrative Expense of Revenue |
53.79% | 46.01% | 48.24% | 41.41% | 35.60% | 26.24% | 29.34% | — |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.08 | 0.03 | 0.03 | 0.00 | 0.01 | 0.00 |
Share Based Compensation of Revenue |
12.20% | 13.39% | 11.42% | 10.12% | 5.15% | 0.66% | 0.00% | — |
Graham Net Nets |
0.42 | 0.35 | 0.24 | 0.26 | 0.30 | 0.28 | 0.28 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 1.15 | 0.62 | 0.00 | 0.00 | — |
Earnings Yield |
(10.10%) | (0.81%) | (1.01%) | 0.18% | 0.02% | 2.75% | 2.75% | — |
Free Cash Flow Yield |
(1.34%) | 2.59% | 0.03% | (1.61%) | 0.02% | 1.57% | 1.57% | — |
Revenue per Share |
1.58 | 1.53 | 1.43 | 1.22 | 1.67 | 3.19 | 0.44 | — |
Operating CF per Share |
(0.04) | 0.19 | 0.04 | (0.09) | 0.06 | 0.52 | (0.10) | — |
Capex per Share |
(0.03) | (0.03) | (0.04) | (0.07) | (0.06) | (0.05) | 0.00 | — |
Free Cash Flow per Share |
(0.07) | 0.17 | 0.00 | (0.16) | 0.00 | 0.47 | (0.10) | — |
Cash per Share |
2.05 | 2.13 | 1.94 | 2.56 | 4.75 | 5.70 | 0.23 | — |
Shareholders Equity per Share |
2.68 | 3.03 | 2.91 | 3.16 | 5.28 | 6.12 | 0.25 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.68 | 3.03 | 2.91 | 3.16 | 5.28 | 6.12 | 0.25 | — |
Free Cash Flow |
(8.62) | 21.94 | 0.45 | (22.10) | 0.27 | 13.61 | (13.75) | — |
Working Capital |
314.19 | 328.78 | 335.83 | 404.98 | 398.55 | 182.09 | 46.73 | — |
Capital Expenditures |
(3.94) | (3.44) | (4.83) | (9.87) | (4.36) | (1.55) | (0.97) | — |
Net Current Asset Value |
272.19 | 292.68 | 290.67 | 360.09 | 373.81 | 166.93 | 29.73 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 96.95 | 38.32 | 38.32 | — |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.06 | 0.03 | 0.02 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 136.77 | 52.30 | 52.30 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.66 | 0.58 | 0.50 | 0.41 | 0.21 | 0.28 | 0.30 | — |
Cash ROIC |
(1.43%) | 3.25% | 0.07% | (2.86%) | 0.03% | 3.95% | (21.75%) | — |
Accounts Receivable Turnover |
3.27 | 3.44 | 3.68 | 4.17 | 5.47 | 5.35 | 3.23 | — |
Accounts Payable Turnover |
16.25 | 20.87 | 21.33 | 16.09 | 16.33 | 15.56 | 11.05 | — |
Inventory Turnover |
2.10 | 1.71 | 1.53 | 1.57 | 1.77 | 1.98 | 1.41 | — |
Average Days of Payables |
24.11 | 22.59 | 13.24 | 27.81 | 22.69 | 26.13 | 29.27 | — |
Days of Inventory on Hand |
182.17 | 179.31 | 265.83 | 278.71 | 240.59 | 204.27 | 230.35 | — |
Average Receivables |
61.55 | 58.26 | 52.40 | 39.31 | 23.38 | 17.37 | 17.93 | — |
Average Payables |
5.97 | 4.28 | 3.92 | 3.92 | 2.99 | 2.64 | 2.64 | — |
Average Inventory |
46.16 | 52.39 | 54.52 | 40.16 | 27.59 | 20.73 | 20.73 | — |
Average Assets |
480.52 | 496.98 | 506.97 | 491.39 | 341.64 | 145.48 | 35.50 | — |
Average Common Equity |
368.74 | 394.40 | 409.31 | 415.47 | 194.68 | (28.86) | (28.86) | — |
Columns are period end dates